Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28472895 | 0.83 | HTT (0.46) | HTTHSD17B3MAPTMEN1ALDH1A1 | |
| SCHEMBL2369098 | 0.80 | TSHR (0.50) | ALDH1A1 | |
| SCHEMBL27499079 | 0.77 | DAGLA (0.53) | FAAHDAGLA | |
| SCHEMBL4783456 | 0.76 | FFAR4 (0.42) | HTTMAPTFFAR1MEN1ALDH1A1 | |
| SCHEMBL11620585 | 0.75 | TYR (0.49) | HTTMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL27500608 | 0.75 | DAGLA (0.51) | FFAR1ALDH1A1FAAHDAGLA | |
| SCHEMBL6052102 | 0.74 | ALDH1A1 (0.47) | MAPTALDH1A1 | |
| SCHEMBL10794438 | 0.72 | HTT (0.61) | HTTHSD17B3PLA2G2APLA2G5MAPT | |
| SCHEMBL9171594 | 0.72 | ALDH1A1 (0.46) | MAPTALDH1A1 | |
| SCHEMBL9806444 | 0.72 | HTT (0.61) | HTTHSD17B3PLA2G2APLA2G5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309336-B1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | BIOSOURCE PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1309336-A4 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | MICROLOGIX BIOTECH INC (CA) | 2005-01-05 | — | — | EP | disclosed |
| US-6737403-B2 | CULTURING MICROORGANISM STREPTOMYCES VIRIDOCHROMOGENES, SSP. KOMABENSIS (ATCC 29814) IN CULTURE MEDIUM, ISOLATING LASPARTOMYCIN, CLEAVING LIPOPHILIC FRAGMENT FROM LASPARTOMYCIN, THEREBY YIELDING LASPARTOMYCIN CORE PEPTIDE | MICROLOGIX BIOTECH INC. (CA) | 2004-05-18 | — | — | US | disclosed |
| EP-1309336-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | Micrologix Biotech, Inc. (CA) | 2003-05-14 | — | — | EP | disclosed |
| US-6511962-B1 | Intermediates useful for synthesizing laspartomycin derivatives as well as the laspartomycin derivatives | MICROLOGIX BIOTECH INC. (CA) | 2003-01-28 | — | — | US | disclosed |
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | BIOSOURCE PHARM, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002005838-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | VIP, LAS1L, PREP | HTT 3341/4885HSD17B3 2405/4885PLA2G2A 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.